Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients. Source
No articles found.
Turning Point Therapeutics is a clinical-stage precision oncology company with a p...
Turning Point Therapeutics is a clinical-stage ...
With demonstrated clinical development and commercialization expertise, VIVUS is d...
With demonstrated clinical development and comm...
We are an established, commercial-stage diagnostics company committed to reducing ...
We are an established, commercial-stage diagnos...
Galectin Therapeutics is a biotechnology company focused on discovery and developm...
Galectin Therapeutics is a biotechnology compan...
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focuse...
Royal Philips (NYSE: PHG, AEX: PHIA) is a leadi...
HJLI specializes in developing and manufacturing bioprosthetic medical devices to ...
HJLI specializes in developing and manufacturin...
Audentes Therapeutics is a leading AAV-based genetic medicines company focused on ...
Audentes Therapeutics is a leading AAV-based ge...
Join the National Investor Network and get the latest information with your interests in mind.